← Back
Rare Disease

Nedosiran (Rivfloza)

Dicerna / Novo Nordisk

RNAi targeting LDHA in primary hyperoxaluria. FDA approved. Competing with lumasiran. Confirmatory PHYOX data ongoing.

Primary Hyperoxaluria Type 1

Linked Studies

NCT04617275PrimaryCOMPLETEDPHASE2

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

DiabetesObesityUpdated Dec 2022
Loading comments…

Also Known As

Other names

nedosiran
Search all trials →Request coverage update